<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lee-may Chen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan S Berek, MD, MMS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Don S Dizon, MD, FACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Ovarian carcinoma is the second most common gynecologic malignancy (second to uterine carcinoma) and the most common cause of gynecologic cancer death in the United States and other resource-abundant countries. (See  <a class="medical medical_review" href="/d/html/83387.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Incidence and risk factors", section on 'Incidence'</a>.)</p><p>The majority of ovarian malignancies (95 percent) are derived from epithelial cells (subtypes include high-grade serous, low-grade serous, endometrioid, clear cell, and mucinous); the remainder arise from other ovarian cell types (germ cell tumors, sex cord-stromal tumors  (<a class="graphic graphic_figure graphicRef72286" href="/d/graphic/72286.html" rel="external">figure 1</a>)) [<a href="#rid1">1</a>].</p><p>High-grade serous epithelial ovarian carcinoma (EOC), fallopian tube, and peritoneal carcinomas are considered a single clinical entity due to their shared clinical behavior and treatment. There is also accumulating evidence of a common pathogenesis for these carcinomas. We will use the term EOC to refer to this group of malignancies in the discussion that follows. Distinctions between these conditions, where present, will be addressed.</p><p>The clinical features and diagnosis of EOC are reviewed here with a focus on the most frequent subtype, epithelial serous malignancies. </p><p>Related topics are discussed in detail separately, including:</p><p class="bulletIndent1"><span class="glyph">●</span>An overview of ovarian carcinomas (see  <a class="medical medical_review" href="/d/html/83397.html" rel="external">"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening of asymptomatic patients (see  <a class="medical medical_review" href="/d/html/7563.html" rel="external">"Screening for ovarian cancer"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histopathology (see  <a class="medical medical_review" href="/d/html/3241.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Histopathology"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epidemiology and risk factors (see  <a class="medical medical_review" href="/d/html/83387.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Incidence and risk factors"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early symptoms (see  <a class="medical medical_review" href="/d/html/5472.html" rel="external">"Early detection of epithelial ovarian cancer: Role of symptom recognition"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Staging and surgical treatment (see  <a class="medical medical_review" href="/d/html/3193.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Surgical staging"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adjuvant therapy (see  <a class="medical medical_review" href="/d/html/3199.html" rel="external">"Adjuvant therapy of early-stage (stage I and II) epithelial ovarian, fallopian tube, or peritoneal cancer"</a> and  <a class="medical medical_review" href="/d/html/3239.html" rel="external">"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer"</a>)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The clinical presentation of EOC may be acute, subacute, or in some cases, found incidentally during examination, imaging, or surgery for another indication. </p><p class="headingAnchor" id="H9533939"><span class="h2">Acute presentation</span><span class="headingEndMark"> — </span>Patients presenting in an acute fashion are typically those with advanced disease who present with a condition that requires urgent evaluation and management.</p><p class="headingAnchor" id="H2445714665"><span class="h3">Ascites</span><span class="headingEndMark"> — </span>Malignancy-related ascites causes abdominal distension by two mechanisms: (1) tumor cells produce fluid in the peritoneal cavity and (2) metastatic disease on the diaphragm prevents fluid from flowing out of the peritoneal cavity. If imaging reveals ascites, paracentesis may be performed for diagnosis and therapeutic purposes. (See <a class="local">'Pelvic and abdominal imaging'</a> below and <a class="local">'Fluid cytology or omental/pleural biopsy'</a> below and  <a class="medical medical_review" href="/d/html/1261.html" rel="external">"Evaluation of adults with ascites", section on 'Diagnosis'</a>.) </p><p class="headingAnchor" id="H9533974"><span class="h3">Pleural effusion</span><span class="headingEndMark"> — </span>Malignant pleural effusion causes shortness of breath  (<a class="graphic graphic_diagnosticimage graphicRef93144" href="/d/graphic/93144.html" rel="external">image 1</a>); if chest imaging reveals a malignant pleural effusion, thoracentesis may be performed. (See  <a class="medical medical_review" href="/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion"</a> and <a class="local">'Fluid cytology or omental/pleural biopsy'</a> below and <a class="local">'Pelvic and abdominal imaging'</a> below.)</p><p class="headingAnchor" id="H9533987"><span class="h3">Bowel obstruction</span><span class="headingEndMark"> — </span>Bowel obstruction often leads to severe nausea and vomiting. In patients with EOC, this is often accompanied by a finding of an abdominal mass on imaging  (<a class="graphic graphic_diagnosticimage graphicRef93145" href="/d/graphic/93145.html" rel="external">image 2</a>). (See  <a class="medical medical_review" href="/d/html/8037.html" rel="external">"Etiologies, clinical manifestations, and diagnosis of mechanical small bowel obstruction in adults"</a> and <a class="local">'Pelvic and abdominal imaging'</a> below.)</p><p class="headingAnchor" id="H17557798"><span class="h3">Venous thromboembolism</span><span class="headingEndMark"> — </span>Infrequently, patients with EOC initially present with venous thromboembolism (VTE  (<a class="graphic graphic_diagnosticimage graphicRef93146" href="/d/graphic/93146.html" rel="external">image 3</a>)) [<a href="#rid2">2,3</a>]. In a retrospective study including over 12,000 patients with ovarian cancer, the incidence of VTE during the year preceding their cancer diagnosis was approximately three times higher than the general population (27 versus 9.5 cases per year; standard incidence rate 2.8, 95% CI 1.9-4.1) [<a href="#rid2">2</a>]. The role of screening for malignancy in patients with VTE is discussed separately. (See  <a class="medical medical_review" href="/d/html/1363.html" rel="external">"Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors", section on 'Evaluation for occult malignancy'</a>.)</p><p class="headingAnchor" id="H9533947"><span class="h2">Subacute presentation</span><span class="headingEndMark"> — </span>More commonly, disease presents in a subacute fashion (eg, pelvic or abdominal pain, bloating, gastrointestinal symptoms). The type or severity of symptoms do not reliably correspond to disease stage. In addition, while EOC had historically been thought to be a silent disease, studies have found that symptoms may occur even at early stages of disease [<a href="#rid4">4-11</a>].</p><p class="headingAnchor" id="H6099199"><span class="h3">Pelvic and abdominal symptoms</span><span class="headingEndMark"> — </span>Pelvic and abdominal symptoms may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Bloating or abdominal distention  (<a class="graphic graphic_diagnosticimage graphicRef93147" href="/d/graphic/93147.html" rel="external">image 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinary urgency or frequency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Difficulty eating, nausea, anorexia, or early satiety.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pelvic or abdominal pain – Anecdotal reports suggest patients with tubal carcinoma present with more intense pain than those with an ovarian carcinoma, possibly due to tubal distension [<a href="#rid12">12</a>].</p><p></p><p>In patients with advanced disease, these symptoms are typically due to the presence of ascites and omental or bowel metastases.</p><p>These symptoms are nonspecific and may also be caused by other conditions (eg, primary gastrointestinal or urologic disease (see <a class="local">'Differential diagnosis'</a> below)). Symptoms that warrant further evaluation for ovarian cancer are those that are of new onset, coexist with other symptoms, occur almost daily, and are more severe than expected. The Gynecologic Cancer Foundation, American Cancer Society, and Society of Gynecologic Oncologists issued a consensus statement regarding early symptoms in 2007  (<a class="graphic graphic_table graphicRef76135" href="/d/graphic/76135.html" rel="external">table 1</a>).</p><p>The role of pelvic or abdominal symptoms in the detection of ovarian cancer is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5472.html" rel="external">"Early detection of epithelial ovarian cancer: Role of symptom recognition"</a>.)</p><p class="headingAnchor" id="H9534089"><span class="h3">Vaginal bleeding</span><span class="headingEndMark"> — </span>Some patients with EOC present with postmenopausal bleeding, although patients with postmenopausal bleeding should be first assessed for uterine pathology before proceeding with an evaluation for ovarian cancer [<a href="#rid13">13,14</a>]. (See <a class="local">'Surveilling for other cancers'</a> below and <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/d/html/5421.html" rel="external">"Approach to the patient with postmenopausal uterine bleeding", section on 'Etiology'</a>.)</p><p>For fallopian tube carcinoma, while postmenopausal bleeding may occur [<a href="#rid15">15</a>], the classic triad of symptoms includes clear or blood-tinged vaginal discharge, pelvic pain, and a pelvic mass. The vaginal discharge, referred to as hydrops tubae profluens, has been regarded as pathognomonic for the disease [<a href="#rid16">16</a>]. However, vaginal discharge is not present in most patients with fallopian tube cancer (only 2 of 12 in one series [<a href="#rid17">17</a>]), and a complaint of vaginal discharge rarely results in the diagnosis of fallopian tube carcinoma.</p><p class="headingAnchor" id="H2666581631"><span class="h3">Rare presentations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphadenopathy </strong>– Palpable inguinal or cervical lymphadenopathy is an uncommon presentation of EOC  (<a class="graphic graphic_diagnosticimage graphicRef93148" href="/d/graphic/93148.html" rel="external">image 5</a>). (See  <a class="medical medical_review" href="/d/html/8386.html" rel="external">"Evaluation of peripheral lymphadenopathy in adults", section on 'Localized lymphadenopathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rectal bleeding</strong> – Rectal bleeding is rare and is unlikely to be the only presenting symptom; further evaluation for EOC is only warranted if other clinical features of EOC are present (eg, adnexal mass, hereditary ovarian cancer syndrome) [<a href="#rid13">13,14</a>]. (See  <a class="medical medical_review" href="/d/html/2546.html" rel="external">"Etiology of lower gastrointestinal bleeding in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paraneoplastic syndromes</strong> – Rarely, patients with EOC may present with, or develop, a paraneoplastic syndrome. Paraneoplastic syndromes associated with EOC include: cerebellar degeneration, polyneuritis, dermatomyositis, hemolytic anemia, disseminated intravascular coagulation, acanthosis, or nephrotic syndrome [<a href="#rid18">18</a>]. These syndromes are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system"</a> and  <a class="medical medical_review" href="/d/html/5615.html" rel="external">"Malignancy and rheumatic disorders"</a> and  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer"</a> and  <a class="medical medical_review" href="/d/html/7606.html" rel="external">"Cutaneous manifestations of internal malignancy"</a> and  <a class="medical medical_review" href="/d/html/7173.html" rel="external">"Overview of kidney disease in patients with cancer"</a> and  <a class="medical medical_review" href="/d/html/7084.html" rel="external">"Cold agglutinin disease"</a>.)</p><p></p><p class="headingAnchor" id="H586132"><span class="h2">Incidental finding</span></p><p class="headingAnchor" id="H601073078"><span class="h3">Adnexal mass</span><span class="headingEndMark"> — </span>A diagnosis of EOC may result from finding an adnexal mass during a routine pelvic examination or imaging study performed for another indication. Patients with advanced disease may present with a pelvic mass that extends beyond the adnexa.</p><p>The clinical presentation of patients with an adnexal mass is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass", section on 'Clinical presentation'</a>.)</p><p class="headingAnchor" id="H3203579043"><span class="h3">Atypical glandular cells on cervical cytology</span><span class="headingEndMark"> — </span>Infrequently, patients with EOC present with atypical glandular cells (AGC) on cervical cytology. In a systematic review including almost 7000 patients with a Pap smear with AGC, 5.2 percent had a malignancy; among patients with malignancy, 5.4 percent were ovarian and 1 percent were fallopian tube carcinoma [<a href="#rid19">19</a>]. Patients with a finding of AGC should be first evaluated for cervical and endometrial carcinoma, but if these evaluations are negative, further evaluation for EOC should be performed. (See  <a class="medical medical_review" href="/d/html/3229.html" rel="external">"Cervical cytology: Evaluation of atypical and malignant glandular cells", section on 'Patients with persistent AGC and negative colposcopy, endometrial biopsy, and conization'</a>.)</p><p class="headingAnchor" id="H4073830051"><span class="h3">Findings during surgery for another indication</span><span class="headingEndMark"> — </span>In some cases, EOC is discovered incidentally at the time of surgery for another indication. For example, patients undergoing risk-reducing salpingo-oophorectomy surgery may be diagnosed with an underlying fallopian tube or ovarian cancer at the time of risk-reducing surgery or with an occult cancer on serial sectioning of the pathology specimens. (See  <a class="medical medical_review" href="/d/html/3250.html" rel="external">"Risk-reducing salpingo-oophorectomy in patients at high risk of epithelial ovarian and fallopian tube cancer", section on 'Occult malignancy on pathology'</a>.)</p><p>If malignancy is recognized intraoperatively, intraoperative consultation from a gynecologic oncologist should be requested, if available. If a gynecologic oncologist is not available and the surgeon is not experienced in operative management of ovarian cancer (eg, lymphadenectomy), it is prudent to terminate the surgery and arrange for prompt consultation with a specialist for a second procedure. (See <a class="local">'Referral to a specialist'</a> below.)</p><p>If ovarian cancer is discovered only upon histologic evaluation following surgery, the patient should be referred to a gynecologic oncologist.</p><p class="headingAnchor" id="H13733315"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H398339062"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Evaluation of patients with features suggestive of EOC is typically a multiphase process:</p><p class="bulletIndent1"><span class="glyph">●</span>An initial evaluation, including complete physical examination, imaging (typically pelvic ultrasound), and laboratory studies, to determine whether an adnexal mass or elevated tumor markers are present; this will dictate whether further evaluation and surgery are indicated. (See <a class="local">'Initial evaluation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subsequent evaluation, including further imaging (eg, computed tomography [CT] or magnetic resonance imaging [MRI]) and possible fluid or tissue sampling to exclude metastatic disease, an extraovarian (or extratubal) primary cancer, or a synchronous endometrial cancer. This evaluation may result in the decision to treat with neoadjuvant chemotherapy prior to surgery. (See <a class="local">'Subsequent evaluation'</a> below and  <a class="medical medical_review" href="/d/html/3239.html" rel="external">"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer", section on 'Neoadjuvant chemotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical exploration to remove the specimen, make a histologic diagnosis, and perform staging. (See <a class="local">'Surgical evaluation'</a> below and <a class="local">'Diagnosis'</a> below.) </p><p></p><p class="headingAnchor" id="H6099223"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>The primary goal of the initial evaluation for EOC is to determine the degree of clinical suspicion of malignancy. If there is a high likelihood of malignancy, the patient should be referred to a gynecologic oncologist. (See <a class="local">'Referral to a specialist'</a> below.)</p><p class="headingAnchor" id="H2903393806"><span class="h3">Physical examination and pelvic imaging</span><span class="headingEndMark"> — </span>The most important element of the evaluation of EOC is the finding of an adnexal mass on pelvic examination and imaging. Pelvic ultrasound is typically the preferred initial imaging study, though patients with an acute presentation may be initially imaged with CT. (See <a class="local">'Acute presentation'</a> above.)</p><p>Findings concerning for malignancy include, but are not limited to, an adnexal mass with a solid component that is not hyperechoic and is often nodular or papillary, Doppler demonstration of flow in the solid component, irregularly thick septations, and ascites. (See  <a class="medical medical_review" href="/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass", section on 'Assessing the risk of malignancy'</a>.)</p><p>Once a suspicious adnexal mass has been identified, laboratory evaluation for tumor markers and additional imaging studies may be performed. (See <a class="local">'Serum biomarkers'</a> below and <a class="local">'Pelvic and abdominal imaging'</a> below.) </p><p>For patients without an adnexal mass, but with symptoms of EOC (eg, abdominal bloating), the decision to proceed with surgery is based on either the combination of EOC-associated symptoms, an elevated tumor marker, and/or imaging findings consistent with peritoneal carcinomatosis. (See <a class="local">'Pelvic and abdominal symptoms'</a> above and <a class="local">'Serum biomarkers'</a> below and <a class="local">'Pelvic and abdominal imaging'</a> below.)</p><p>Management of benign-appearing adnexal masses is discussed separately. (See  <a class="medical medical_review" href="/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass"</a>.)</p><p class="headingAnchor" id="H2790765169"><span class="h3">Serum biomarkers</span><span class="headingEndMark"> — </span>A baseline serum cancer antigen 125 (CA 125) should be drawn. Up to 85 percent of patients with EOC will have an elevated CA 125 [<a href="#rid20">20</a>], and posttreatment CA 125 testing is used to evaluate for response to treatment and recurrence [<a href="#rid21">21</a>].</p><p>Other tumor markers (eg, human epididymis protein 4, carcinoembryonic antigen, cancer antigen 19-9, lactate dehydrogenase, alpha fetoprotein) should be ordered as clinically indicated. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/16557.html" rel="external">"Adnexal mass: Role of serum biomarkers in diagnosing epithelial carcinoma of the ovary, fallopian tube, or peritoneum"</a> and  <a class="medical medical_review" href="/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass", section on 'Role of tumor markers and multimodal tests'</a>.)</p><p class="headingAnchor" id="H1152411426"><span class="h2">Subsequent evaluation</span></p><p class="headingAnchor" id="H1177390157"><span class="h3">Assessing for metastatic disease</span><span class="headingEndMark"> — </span>The medical history and physical examination of all patients with suspected EOC should include an assessment for symptoms and findings associated with metastatic disease (eg, gastrointestinal symptoms, abdominal distention, ascites, pleural effusion, inguinal or cervical lymphadenopathy). Preoperative assessment for metastatic disease helps the surgeon anticipate the need for cytoreduction and identify patients who are poor candidates for aggressive initial surgical cytoreduction due to imaging findings of extensive disease (eg, liver or pulmonary metastases, disease in the porta hepatis, massive ascites) and may be candidates for neoadjuvant chemotherapy. (See  <a class="medical medical_review" href="/d/html/3239.html" rel="external">"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer", section on 'Neoadjuvant chemotherapy'</a>.)</p><p class="headingAnchor" id="H3548393255"><span class="h4">Pelvic and abdominal imaging</span><span class="headingEndMark"> — </span>Imaging studies can help assess for the presence of ascites and disease spread. Abdominal and pelvic CT  (<a class="graphic graphic_diagnosticimage graphicRef93149" href="/d/graphic/93149.html" rel="external">image 6</a> and <a class="graphic graphic_diagnosticimage graphicRef93150" href="/d/graphic/93150.html" rel="external">image 7</a>) or MRI  (<a class="graphic graphic_diagnosticimage graphicRef93152" href="/d/graphic/93152.html" rel="external">image 8</a>) are the most commonly used modalities. In our practice, we obtain an abdominal and pelvic CT because it is less expensive and more comfortable for the patient than MRI. If the patient has a contrast allergy that precludes use of CT, we order an MRI.</p><p>Some data suggest that positron emission tomography alone or combined with CT increases the detection of metastatic EOC compared with CT alone or MRI; further study of the preoperative use of this imaging modality is needed [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H122358795"><span class="h4">Other imaging studies</span><span class="headingEndMark"> — </span>Chest CT is often performed at the time of abdominal and pelvic CT to evaluate for pleural effusion, pulmonary metastases, and mediastinal lymphadenopathy  (<a class="graphic graphic_diagnosticimage graphicRef93156" href="/d/graphic/93156.html" rel="external">image 9</a>). Chest radiography, while not performed for staging, may also show evidence of disease spread, if present  (<a class="graphic graphic_diagnosticimage graphicRef93154" href="/d/graphic/93154.html" rel="external">image 10</a>).</p><p>Bone scans and brain scans are unnecessary unless symptoms or signs suggest metastases to these sites.</p><p class="headingAnchor" id="H712775084"><span class="h4">Fluid cytology or omental/pleural biopsy</span><span class="headingEndMark"> — </span>Some patients (eg, poor performance status, advanced disease that clinically appears unresectable) require neoadjuvant chemotherapy rather than primary surgery. For these patients, it is imperative a diagnosis be made prior to the start of medical treatment; this can be accomplished in several ways:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluid cytology</strong> – In patients with ascites or pleural effusion, paracentesis or thoracentesis may be performed, respectively. Cytologic evaluation can establish the diagnosis of malignancy, but the overall sensitivity of these tests is variable, and more than one sample may be needed. This is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1240.html" rel="external">"Malignancy-related ascites", section on 'Cytology'</a> and  <a class="medical medical_review" href="/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion", section on 'Cytology, flow cytometry, and cancer-related biomarkers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Omental/pleural biopsies</strong> – In patients with suspected omental or pleural metastases, biopsies may help guide diagnosis as well as management decisions [<a href="#rid23">23,24</a>]. In a retrospective case series including 159 patients with peritoneal carcinomatosis, CT- or ultrasound-guided biopsy provided a site-specific diagnosis in 93 percent of patients [<a href="#rid24">24</a>]. The biopsy specimen should contain sufficient tissue so that immunostaining can be performed to help characterize a malignancy (ie, by type and grade). This is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1240.html" rel="external">"Malignancy-related ascites", section on 'Omental biopsy'</a> and  <a class="medical medical_review" href="/d/html/6707.html" rel="external">"Diagnostic evaluation of the hemodynamically stable adult with a pleural effusion", section on 'Pleural biopsy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Image-guided biopsy of the ovary is <strong>not recommended</strong>; incising or rupturing the mass can lead to spillage of malignant cells, which may result in a more advanced stage of disease and adversely affects prognosis  (<a class="graphic graphic_table graphicRef113545" href="/d/graphic/113545.html" rel="external">table 2</a>) [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/3304.html" rel="external">"Oophorectomy and ovarian cystectomy", section on 'Spillage of malignant cells'</a>.)</p><p></p><p>Treatment with neoadjuvant chemotherapy is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3239.html" rel="external">"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer", section on 'Neoadjuvant chemotherapy'</a>.)</p><p class="headingAnchor" id="H1953594675"><span class="h3">Surveilling for other cancers</span></p><p class="bulletIndent1"><span class="glyph">●</span>Although it is rare for a de novo metastatic breast or colon cancer to present similarly to EOC, those with a prior history of these cancers may present with metastatic disease to the ovary, or with symptoms that mimic ovarian cancer  (<a class="graphic graphic_diagnosticimage graphicRef93157" href="/d/graphic/93157.html" rel="external">image 11</a>). In studies of 50 or more cases of metastatic neoplasms to the ovary, the sites of primary tumors included colon cancer (15 to 32 percent), breast (8 to 28 percent), gastric (6 to 22 percent), and appendix (2 to 20 percent) [<a href="#rid26">26-28</a>]. The clinical features and diagnosis of breast and gastrointestinal cancers are discussed in detail separately. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/d/html/2496.html" rel="external">"Clinical presentation, diagnosis, and staging of colorectal cancer"</a> and  <a class="medical medical_review" href="/d/html/2527.html" rel="external">"Well-differentiated neuroendocrine tumors of the appendix"</a> and  <a class="medical medical_review" href="/d/html/2513.html" rel="external">"Clinical features, diagnosis, and staging of gastric cancer"</a> and  <a class="medical medical_review" href="/d/html/744.html" rel="external">"Clinical features, diagnosis, and staging of newly diagnosed breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among gynecologic malignancies other than ovarian cancer, endometrial cancer is the most likely to present with an adnexal mass. Thus, patients with abnormal uterine bleeding or a uterine mass should undergo endometrial sampling prior to surgical exploration for presumed EOC. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/d/html/3232.html" rel="external">"Overview of the evaluation of the endometrium for malignant or premalignant disease"</a>.)</p><p></p><p class="bulletIndent1">Synchronous primary cancers of the ovary and endometrium can also occur and have been reported in approximately 10 percent of patients with ovarian cancer and 5 percent of patients with endometrial cancer [<a href="#rid29">29</a>]. Patients at an increased risk for both ovarian and endometrial cancer are those with Lynch syndrome  (<a class="graphic graphic_table graphicRef52285" href="/d/graphic/52285.html" rel="external">table 3</a>) and those with an estrogen-secreting tumor (although these are sex cord-stromal tumors rather than epithelial carcinoma  (<a class="graphic graphic_table graphicRef55817" href="/d/graphic/55817.html" rel="external">table 4</a>)). Other risk factors for synchronous cancers include younger age, obesity, and nulliparity, which suggest a hormonal effect [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention", section on 'Estrogen-secreting tumors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cervical, vaginal, or vulvar cancer are not commonly mistaken for ovarian cancer. These tumors may present with a pelvic mass but, rather than an isolated adnexal mass, these masses often occur at the site of origin of these cancers. (See  <a class="medical medical_review" href="/d/html/3179.html" rel="external">"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3221.html" rel="external">"Vaginal cancer"</a> and  <a class="medical medical_review" href="/d/html/3237.html" rel="external">"Vulvar cancer: Epidemiology, diagnosis, histopathology, and treatment"</a>.)</p><p></p><p class="headingAnchor" id="H4105511697"><span class="h2">Surgical evaluation</span><span class="headingEndMark"> — </span>If symptoms associated with EOC and/or abdominal distention or ascites are present and tumor markers associated with EOC are elevated, a diagnostic laparoscopy should be considered as part of the evaluation and to assess cytoreductive feasibility (ie, Fagotti score). (See <a class="local">'Diagnosis'</a> below and  <a class="medical medical_review" href="/d/html/122088.html" rel="external">"Cancer of the ovary, fallopian tube, and peritoneum: Surgical cytoreduction", section on 'Laparoscopy'</a>.)</p><p class="headingAnchor" id="H6099260"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>EOCs are histologic diagnoses. (See  <a class="medical medical_review" href="/d/html/3241.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Histopathology"</a>.)</p><p>For most patients, tissue is obtained during surgical removal of an ovary or fallopian tube or biopsies of the peritoneum. When the diagnosis is confirmed, staging and cytoreduction can be performed. Patients with early-stage disease (ie, no malignant cells in ascites or peritoneal cytology) benefit from removal of the adnexal mass intact since incising or rupturing the mass results in a more advanced stage of disease and adversely affects prognosis. In the case of metastatic disease, the goal of surgery is to resect the tumor to minimal (ideally zero) gross residual disease. (See  <a class="medical medical_review" href="/d/html/3193.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Surgical staging"</a>.)</p><p>In approximately one-third of patients with advanced disease, the diagnosis is based on tissue or fluid obtained via image-guided biopsy, paracentesis, or thoracentesis. This is discussed in more detail above. (See <a class="local">'Fluid cytology or omental/pleural biopsy'</a> above.)</p><p>Even though EOCs are considered a single clinical entity due to their shared clinical behavior and common pathogenesis, we attempt to distinguish between these malignancies and assign an apparent primary site (ie, ovary, tube, or peritoneum) as part of staging [<a href="#rid21">21,31</a>]. Treatment, however, is the same for all three sites. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/d/html/3199.html" rel="external">"Adjuvant therapy of early-stage (stage I and II) epithelial ovarian, fallopian tube, or peritoneal cancer"</a> and  <a class="medical medical_review" href="/d/html/3239.html" rel="external">"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer"</a>.)</p><p class="headingAnchor" id="H31"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Because the diagnosis of EOC is based on histologic findings, and many of the symptoms associated with EOC (eg, abdominal pressure or pain, gastrointestinal symptoms, urologic symptoms) are nonspecific, it is important to carefully assess for other conditions. The differential diagnosis typically depends on the presence or absence of an adnexal mass and/or peritoneal carcinomatosis.</p><p>If an adnexal mass is present:</p><p class="bulletIndent1"><span class="glyph">●</span>The mass may be benign  (<a class="graphic graphic_table graphicRef107713" href="/d/graphic/107713.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/d/html/3204.html" rel="external">"Adnexal mass: Differential diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignant adnexal masses may be due to primary EOC, a nonepithelial primary ovarian cancer (eg, germ cell, sex-cord stromal, sarcoma [rare]), or metastatic from another site. (See  <a class="medical medical_review" href="/d/html/3236.html" rel="external">"Ovarian germ cell tumors: Pathology, epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/16833.html" rel="external">"Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults"</a> and  <a class="medical medical_review" href="/d/html/14259.html" rel="external">"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma"</a> and <a class="local">'Surveilling for other cancers'</a> above.)</p><p></p><p>In the absence of an adnexal mass, the differential diagnosis is broad and depends on other findings:</p><p class="bulletIndent1"><span class="glyph">●</span>If ascites or pleural effusion is present, the patient should be evaluated for other conditions associated with these conditions. (See  <a class="medical medical_review" href="/d/html/1261.html" rel="external">"Evaluation of adults with ascites"</a> and  <a class="medical medical_review" href="/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If postmenopausal bleeding is present, the patient should be assessed for uterine pathology. (See <a class="local">'Surveilling for other cancers'</a> above and  <a class="medical medical_review" href="/d/html/5421.html" rel="external">"Approach to the patient with postmenopausal uterine bleeding"</a> and  <a class="medical medical_review" href="/d/html/3232.html" rel="external">"Overview of the evaluation of the endometrium for malignant or premalignant disease"</a>.) </p><p></p><p>If peritoneal carcinomatosis is found on imaging:</p><p class="bulletIndent1"><span class="glyph">●</span>There is a high index of suspicion for peritoneal carcinoma; however, findings suggestive of peritoneal carcinomatosis may result from other intraabdominal malignancies or metastasizing conditions associated with leiomyomas. (See  <a class="medical medical_review" href="/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site"</a> and  <a class="medical medical_review" href="/d/html/15676.html" rel="external">"Uterine fibroids (leiomyomas): Variants and smooth muscle tumors of uncertain malignant potential", section on 'Leiomyomas with disseminated, intravascular, or metastatic growth patterns'</a>.)</p><p></p><p class="headingAnchor" id="H1886145481"><span class="h1">TESTING FOR HEREDITARY CANCER SYNDROMES</span><span class="headingEndMark"> — </span>All patients with a diagnosis of ovarian, fallopian tube, or peritoneal carcinoma should have genetic risk evaluation, irrespective of their family history, as the presence of a familial cancer syndrome (eg, <em>BRCA1</em> or <em>BRCA2, </em>Lynch syndrome) may impact treatment, posttreatment care, and testing of other family members (ie, cascade testing). This is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/83397.html" rel="external">"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum", section on 'Testing for hereditary cancer syndromes'</a> and  <a class="medical medical_review" href="/d/html/753.html" rel="external">"Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes"</a>.)</p><p class="headingAnchor" id="H13734725"><span class="h1">REFERRAL TO A SPECIALIST</span><span class="headingEndMark"> — </span>Patients in whom there is a high suspicion of EOC (eg, findings suggesting of metastatic EOC, elevated serum cancer antigen 125 level in a patient with a complex adnexal mass) should be referred to a gynecologic oncologist. There is evidence that prognosis is improved when EOC staging and cytoreduction is performed by a gynecologic oncologist. </p><p>Criteria for referral to a gynecologic oncologist are shown in the table  (<a class="graphic graphic_table graphicRef55063" href="/d/graphic/55063.html" rel="external">table 6</a>); a computer algorithm (the Risk of Ovarian Cancer Algorithm [ROCA]) that incorporates age-specific incidence of cancer, absolute CA 125 level, and rate of CA 125 change over time can also be used to estimate ovarian cancer risk. (See  <a class="medical medical_review" href="/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass"</a> and  <a class="medical medical_review" href="/d/html/7563.html" rel="external">"Screening for ovarian cancer", section on 'Multimodal (CA 125 and TVUS) tests'</a>.)</p><p>Despite the above guidance, Black patients with ovarian cancer are less likely to receive consultation with a gynecologic oncologist compared with White patients [<a href="#rid32">32</a>]; this is consistent with other health disparity patterns and is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/117408.html" rel="external">"Racial and ethnic inequities in obstetric and gynecologic care and role of implicit biases"</a>.)</p><p class="headingAnchor" id="H3879180903"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119533.html" rel="external">"Society guideline links: Ovarian, fallopian tube, and peritoneal cancer"</a>.)</p><p class="headingAnchor" id="H47"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15417.html" rel="external">"Patient education: Ovarian cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/851.html" rel="external">"Patient education: Treatment of ovarian cancer (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/864.html" rel="external">"Patient education: Ovarian cancer diagnosis and staging (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H48"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical significance</strong> – Epithelial ovarian carcinoma (EOC), fallopian tube, and peritoneal carcinomas are considered a single clinical entity due to their shared clinical behavior and treatment. There is also accumulating evidence of a common pathogenesis for these carcinomas. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">Nonetheless, we attempt to distinguish between these malignancies and assign an apparent primary site (ie, ovary, tube, or peritoneum) as part of the staging process. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The clinical presentation of EOC may be acute (eg, pleural effusion, bowel obstruction), subacute (eg, pelvic and abdominal symptoms), or in some cases, found incidentally during examination, imaging, or surgery for another indication (eg, adnexal mass, occult fallopian tube carcinoma after salpingectomy). (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – Evaluation of patients with features suggestive of EOC is typically a multi-phase process and includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An initial evaluation, including physical examination, imaging (typically pelvic ultrasound), and laboratory studies to determine whether an adnexal mass and/or serum biomarkers  (<a class="graphic graphic_table graphicRef55817" href="/d/graphic/55817.html" rel="external">table 4</a>) are present. (See <a class="local">'Initial evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Subsequent evaluation, including further imaging (eg, CT or MRI) and possible fluid or tissue sampling to exclude metastatic disease, an extraovarian (or extratubal) primary cancer, or a synchronous endometrial cancer. (See <a class="local">'Subsequent evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgical evaluation for removal of the intact specimen, histologic diagnosis, and staging. (See <a class="local">'Surgical evaluation'</a> above and <a class="local">'Diagnosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – EOC is a histologic diagnosis. For most patients, tissue is obtained during surgical removal of an ovary or fallopian tube. Less commonly, the diagnosis is based on tissue or fluid obtained via image-guided biopsy (eg, omental or pleural biopsy), paracentesis, or thoracentesis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">Image-guided biopsy of the ovary is <strong>not</strong> recommended; incising or rupturing the mass can lead to spillage of malignant cells, which may result in a more advanced stage of disease and adversely affects prognosis. (See <a class="local">'Fluid cytology or omental/pleural biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential</strong> <strong>Diagnosis</strong> – The differential diagnosis typically depends on the presence or absence of an adnexal mass and/or peritoneal carcinomatosis. If an adnexal mass is present, the differential diagnosis includes both benign and malignant conditions  (<a class="graphic graphic_table graphicRef107713" href="/d/graphic/107713.html" rel="external">table 5</a>). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing for hereditary cancer syndromes</strong> – All patients with a diagnosis of EOC, irrespective of their family history, should have testing for hereditary cancer syndromes (eg, <em>BRCA1</em> or <em>BRCA2, </em>Lynch syndrome). (See <a class="local">'Testing for hereditary cancer syndromes'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to refer</strong> – Patients in whom there is a high suspicion of EOC should be referred to a gynecologic oncologist  (<a class="graphic graphic_table graphicRef55063" href="/d/graphic/55063.html" rel="external">table 6</a>). (See <a class="local">'Referral to a specialist'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Lacey JV, Sherman ME. Ovarian neoplasia. In: Robboy's Pathology of the Female Reproductive Tract, 2nd ed, Robboy SL, Mutter GL, Prat J, et al. (Eds), Churchill Livingstone Elsevier, Oxford 2009. p.601.</li><li><a class="nounderline abstract_t">White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005; 165:1782.</a></li><li><a class="nounderline abstract_t">Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343:1846.</a></li><li><a class="nounderline abstract_t">Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000; 89:2068.</a></li><li><a class="nounderline abstract_t">Olson SH, Mignone L, Nakraseive C, et al. Symptoms of ovarian cancer. Obstet Gynecol 2001; 98:212.</a></li><li><a class="nounderline abstract_t">Vine MF, Ness RB, Calingaert B, et al. Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol 2001; 83:466.</a></li><li><a class="nounderline abstract_t">Yawn BP, Barrette BA, Wollan PC. Ovarian cancer: the neglected diagnosis. Mayo Clin Proc 2004; 79:1277.</a></li><li><a class="nounderline abstract_t">Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 291:2705.</a></li><li><a class="nounderline abstract_t">Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007; 109:221.</a></li><li><a class="nounderline abstract_t">Devlin SM, Diehr PH, Andersen MR, et al. Identification of ovarian cancer symptoms in health insurance claims data. J Womens Health (Larchmt) 2010; 19:381.</a></li><li><a class="nounderline abstract_t">Chan JK, Tian C, Kesterson JP, et al. Symptoms of Women With High-Risk Early-Stage Ovarian Cancer. Obstet Gynecol 2022; 139:157.</a></li><li><a class="nounderline abstract_t">Friedrich M, Villena-Heinsen C, Schweizer J, et al. Primary tubal carcinoma: a retrospective analysis of four cases with a literature review. Eur J Gynaecol Oncol 1998; 19:138.</a></li><li><a class="nounderline abstract_t">Hippisley-Cox J, Coupland C. Identifying women with suspected ovarian cancer in primary care: derivation and validation of algorithm. BMJ 2011; 344:d8009.</a></li><li><a class="nounderline abstract_t">Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ 2009; 339:b2998.</a></li><li><a class="nounderline abstract_t">Clayton NL, Jaaback KS, Hirschowitz L. Primary fallopian tube carcinoma - the experience of a UK cancer centre and a review of the literature. J Obstet Gynaecol 2005; 25:694.</a></li><li><a class="nounderline abstract_t">SINHA AC. Hydrops tubae profluens as a presenting symptom in primary carcinoma of the fallopian tube: report of two cases and review of literature. Br Med J 1959; 2:996.</a></li><li><a class="nounderline abstract_t">Ou YC, Huang HY, Huang CC, et al. Primary fallopian tube carcinoma: clinicopathological analysis of 12 cases. Taiwan J Obstet Gynecol 2011; 50:141.</a></li><li><a class="nounderline abstract_t">Shanbhogue AK, Shanbhogue DK, Prasad SR, et al. Clinical syndromes associated with ovarian neoplasms: a comprehensive review. Radiographics 2010; 30:903.</a></li><li><a class="nounderline abstract_t">Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 2006; 107:701.</a></li><li><a class="nounderline abstract_t">González-Martín A, Harter P, Leary A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34:833.</a></li><li><a class="nounderline abstract_t">Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014; 124:1.</a></li><li><a class="nounderline abstract_t">Musto A, Rampin L, Nanni C, et al. Present and future of PET and PET/CT in gynaecologic malignancies. Eur J Radiol 2011; 78:12.</a></li><li><a class="nounderline abstract_t">Diaz JP, Abu-Rustum NR, Sonoda Y, et al. Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients. Gynecol Oncol 2010; 116:483.</a></li><li><a class="nounderline abstract_t">Hewitt MJ, Anderson K, Hall GD, et al. Women with peritoneal carcinomatosis of unknown origin: Efficacy of image-guided biopsy to determine site-specific diagnosis. BJOG 2007; 114:46.</a></li><li><a class="nounderline abstract_t">Mehdi G, Maheshwari V, Afzal S, et al. Image-guided fine-needle aspiration cytology of ovarian tumors: An assessment of diagnostic efficacy. J Cytol 2010; 27:91.</a></li><li><a class="nounderline abstract_t">Moore RG, Chung M, Granai CO, et al. Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol 2004; 93:87.</a></li><li><a class="nounderline abstract_t">de Waal YR, Thomas CM, Oei AL, et al. Secondary ovarian malignancies: frequency, origin, and characteristics. Int J Gynecol Cancer 2009; 19:1160.</a></li><li><a class="nounderline abstract_t">Kondi-Pafiti A, Kairi-Vasilatou E, Iavazzo C, et al. Metastatic neoplasms of the ovaries: a clinicopathological study of 97 cases. Arch Gynecol Obstet 2011; 284:1283.</a></li><li><a class="nounderline abstract_t">Zaino R, Whitney C, Brady MF, et al. Simultaneously detected endometrial and ovarian carcinomas--a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol 2001; 83:355.</a></li><li><a class="nounderline abstract_t">Soliman PT, Slomovitz BM, Broaddus RR, et al. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol 2004; 94:456.</a></li><li><a class="nounderline abstract_t">Seidman JD, Zhao P, Yemelyanova A. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 2011; 120:470.</a></li><li><a class="nounderline abstract_t">Gupta A, Chen Q, Wilson LE, et al. Factor Analysis of Health Care Access With Ovarian Cancer Surgery and Gynecologic Oncologist Consultation. JAMA Netw Open 2023; 6:e2254595.</a></li></ol></div><div id="topicVersionRevision">Topic 3238 Version 61.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Lacey JV, Sherman ME. Ovarian neoplasia. In: Robboy's Pathology of the Female Reproductive Tract, 2nd ed, Robboy SL, Mutter GL, Prat J, et al. (Eds), Churchill Livingstone Elsevier, Oxford 2009. p.601.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16087828" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11117976" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prognosis of cancers associated with venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11066047" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ovarian carcinoma diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11506835" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Symptoms of ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11733956" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15473410" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ovarian cancer: the neglected diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187051" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Frequency of symptoms of ovarian cancer in women presenting to primary care clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17154394" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Development of an ovarian cancer symptom index: possibilities for earlier detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20156131" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Identification of ovarian cancer symptoms in health insurance claims data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34991145" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Symptoms of Women With High-Risk Early-Stage Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9611053" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Primary tubal carcinoma: a retrospective analysis of four cases with a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22217630" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Identifying women with suspected ovarian cancer in primary care: derivation and validation of algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19706933" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Risk of ovarian cancer in women with symptoms in primary care: population based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263546" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Primary fallopian tube carcinoma - the experience of a UK cancer centre and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14447118" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hydrops tubae profluens as a presenting symptom in primary carcinoma of the fallopian tube: report of two cases and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791297" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Primary fallopian tube carcinoma: clinicopathological analysis of 12 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20631359" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical syndromes associated with ovarian neoplasms: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507944" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical significance of atypical glandular cells on cervical cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37597580" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24219974" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Staging classification for cancer of the ovary, fallopian tube, and peritoneum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20116952" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Present and future of PET and PET/CT in gynaecologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19945741" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17233859" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Women with peritoneal carcinomatosis of unknown origin: Efficacy of image-guided biopsy to determine site-specific diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21187883" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Image-guided fine-needle aspiration cytology of ovarian tumors: An assessment of diagnostic efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15047218" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Incidence of metastasis to the ovaries from nongenital tract primary tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19823050" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Secondary ovarian malignancies: frequency, origin, and characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21311903" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Metastatic neoplasms of the ovaries: a clinicopathological study of 97 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11606097" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Simultaneously detected endometrial and ovarian carcinomas--a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15297188" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21159368" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36723938" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Factor Analysis of Health Care Access With Ovarian Cancer Surgery and Gynecologic Oncologist Consultation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
